Table of Contents

company-logo

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

VistaGen Therapeutics Dividend Announcement

• VistaGen Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on VistaGen Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

VistaGen Therapeutics Dividend History

VistaGen Therapeutics Dividend Yield

VistaGen Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing VistaGen Therapeutics stock? Use our calculator to estimate your expected dividend yield:

VistaGen Therapeutics Financial Ratios

P/E ratio-2338.16
PEG ratio4893.14
P/B ratio995.01
ROE-36.35%
Payout ratio0.00%
Current ratio13.29
Quick ratio13.29
Cash Ratio11.20

VistaGen Therapeutics Dividend FAQ

Does VistaGen Therapeutics stock pay dividends?
VistaGen Therapeutics does not currently pay dividends to its shareholders.
Has VistaGen Therapeutics ever paid a dividend?
No, VistaGen Therapeutics has no a history of paying dividends to its shareholders. VistaGen Therapeutics is not known for its dividend payments.
Why doesn't VistaGen Therapeutics pay dividends?
There are several potential reasons why VistaGen Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will VistaGen Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While VistaGen Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is VistaGen Therapeutics a dividend aristocrat?
VistaGen Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is VistaGen Therapeutics a dividend king?
VistaGen Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is VistaGen Therapeutics a dividend stock?
No, VistaGen Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy VistaGen Therapeutics stocks?
To buy VistaGen Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy VistaGen Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.